NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STAPHCILLIN (methicillin sodium) is an injectable beta-lactam antibiotic developed by Bristol Myers Squibb for treating staphylococcal infections. This product is in pre-launch stage as an NDA submission, positioning it as a potential treatment option for serious gram-positive bacterial infections requiring parenteral therapy.
Pre-Launch
Pre-launch stage offers opportunity to build commercial infrastructure from ground level, with team expansion likely contingent on regulatory approval and market adoption.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STAPHCILLIN presents a foundational career opportunity during the critical pre-launch phase, where professionals can directly influence regulatory strategy, competitive positioning, and commercial infrastructure. Success in this role requires expertise in antibiotic markets, hospital/institutional selling, and regulatory intelligence.
Regulatory Affairs Specialist
Worked on STAPHCILLIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.